|
04-2024
|
R01 (Resub) - Regional and lobular heterogeneity of huma
R01 (Resub) - Regional and lobular heterogeneity of huma
|
|
12-2023
|
Human Pancreas Analysis Program-T2D
Human Pancreas Analysis Program-T2D
|
|
09-2023
|
The Network for Pancreatic Organ donors with Diabetes (nPOD) : A Collaborative Type 1 Diabetes Research Project
The Network for Pancreatic Organ donors with Diabetes (nPOD) : A Collaborative Type 1 Diabetes Research Project
|
|
09-2023
|
Network for Pancreatic Organ Donors - nPOD
Network for Pancreatic Organ Donors - nPOD
|
|
09-2023
|
Collaborative Type 1 Diabetes Research Project: The Network for Pancreatic Organ donors with Diabetes (nPOD)
Collaborative Type 1 Diabetes Research Project: The Network for Pancreatic Organ donors with Diabetes (nPOD)
|
|
06-2023
|
A 3D Tissue Map of the Human Lymphatic System
A 3D Tissue Map of the Human Lymphatic System
|
|
05-2023
|
Immune Function and the Progression to Type 1 Diabetes
Immune Function and the Progression to Type 1 Diabetes
|
|
01-2023
|
Human Atlas of Neonatal Developmental and Early Life Pancreas / Immunity (HANDEL)-P/I Continuation
Human Atlas of Neonatal Developmental and Early Life Pancreas / Immunity (HANDEL)-P/I Continuation
|
|
09-2022
|
T cell receptor sequencing in type 1 diabetes - biomarker discovery and technology development
T cell receptor sequencing in type 1 diabetes - biomarker discovery and technology development
|
|
08-2022
|
Validating KIRAs as B cell-sparing drugs in islets from human patients with T1D
Validating KIRAs as B cell-sparing drugs in islets from human patients with T1D
|
|
08-2022
|
Interdisciplinary Graduate Program in Type 1 Diabetes and Biomedical Engineering
Interdisciplinary Graduate Program in Type 1 Diabetes and Biomedical Engineering
|
|
06-2022
|
Blanche J. Salisbury Diabetes Research Fund
Blanche J. Salisbury Diabetes Research Fund
|
|
06-2022
|
Data coordinating Center for Type 1 Diabetes TrialNet (UC4)###
Data coordinating Center for Type 1 Diabetes TrialNet (UC4)###
|
|
03-2022
|
B-lymphocyte targeting therapies for autoimmune diabetes
B-lymphocyte targeting therapies for autoimmune diabetes
|
|
08-2021
|
Clinical Trial: Evaluation of safety, tolerability and
Clinical Trial: Evaluation of safety, tolerability and
|
|
08-2021
|
Identification of Anti-Neo-Antigen AutoAntibodies in Type 1 Diabetes
Identification of Anti-Neo-Antigen AutoAntibodies in Type 1 Diabetes
|
|
07-2021
|
Targeted nanodelivery in T1D
Targeted nanodelivery in T1D
|
|
07-2021
|
Integrated Program for Human Pancreas Procurement and Analysis
Integrated Program for Human Pancreas Procurement and Analysis
|
|
06-2021
|
TrialNet Clinical Center infrastructure support
TrialNet Clinical Center infrastructure support
|
|
06-2021
|
Data Coordinating Center for Type 1 Diabetes TrialNet (U
Data Coordinating Center for Type 1 Diabetes TrialNet (U
|
|
04-2021
|
The George S. Eisenbarth nPOD Award for Team Science
The George S. Eisenbarth nPOD Award for Team Science
|
|
10-2020
|
2020 nPOD Annual Meeting Conference Grant
2020 nPOD Annual Meeting Conference Grant
|
|
08-2020
|
In situ characterization of human alpha cell physiology in type 1 diabetes pathogenesis
In situ characterization of human alpha cell physiology in type 1 diabetes pathogenesis
|
|
08-2020
|
Neural regulation of alpha cell function and dysregulation in type 1 diabetes
Neural regulation of alpha cell function and dysregulation in type 1 diabetes
|
|
05-2020
|
Single-Cell Analyses of Human Islets in T1D Using Highly Multiplexed Imaging
Single-Cell Analyses of Human Islets in T1D Using Highly Multiplexed Imaging
|
|
05-2020
|
Roles of the Insulin-like Growth Factor Axis in Pre-Type 1 Diabetes Immune Regulation
Roles of the Insulin-like Growth Factor Axis in Pre-Type 1 Diabetes Immune Regulation
|
|
05-2020
|
A Novel Combination Therapy for Type 1 Diabetes Prevention
A Novel Combination Therapy for Type 1 Diabetes Prevention
|
|
04-2020
|
TrialNet: University of Florida Clinical Center and Network
TrialNet: University of Florida Clinical Center and Network
|
|
01-2020
|
Human Atlas of the Neonatal Development and Early Life Pancreas (Handel-P)
Human Atlas of the Neonatal Development and Early Life Pancreas (Handel-P)
|
|
10-2019
|
2019 nPOD Annual Meeting Conference Grant
2019 nPOD Annual Meeting Conference Grant
|
|
10-2019
|
The JDRF nPOD Viral Work group: nPOD-V
The JDRF nPOD Viral Work group: nPOD-V
|
|
06-2019
|
Serum protein biomarkers for predicting type 1 diabetes development
Serum protein biomarkers for predicting type 1 diabetes development
|
|
06-2019
|
Biomaterial Delivery System for Type 1 Diabetes Vaccine
Biomaterial Delivery System for Type 1 Diabetes Vaccine
|
|
06-2019
|
Characterization of T cell Autoreactivity in Type 1 Diabetes
Characterization of T cell Autoreactivity in Type 1 Diabetes
|
|
12-2018
|
nPOD Annual Meeting Costs - 2018
nPOD Annual Meeting Costs - 2018
|
|
06-2018
|
Immune Function and the Progression to Type 1 Diabetes
Immune Function and the Progression to Type 1 Diabetes
|
|
03-2018
|
B-lymphocyte Targeting Therapies for Autoimmune Diabetes
B-lymphocyte Targeting Therapies for Autoimmune Diabetes
|
|
03-2018
|
NPOD Coordinating Center
NPOD Coordinating Center
|
|
02-2018
|
NIDDK Type 1 Diabetes TrialNet Data Coordinating Center
NIDDK Type 1 Diabetes TrialNet Data Coordinating Center
|
|
12-2017
|
nPOD Annual Meeting Costs - 2017 & 2018
nPOD Annual Meeting Costs - 2017 & 2018
|
|
12-2017
|
Helmsley Trust Diabetes Cell Repository
Helmsley Trust Diabetes Cell Repository
|
|
06-2017
|
Assessment of cytokines in human islets from patients with type 1 diabetes
Assessment of cytokines in human islets from patients with type 1 diabetes
|
|
02-2017
|
NIDDK Type 1 diabetes trialnet data coordinating center
NIDDK Type 1 diabetes trialnet data coordinating center
|
|
12-2016
|
Measuring markers and cytokines in human serum and plasma to determine phenotype and a genotype correlations in Type 1 Diabetes
Measuring markers and cytokines in human serum and plasma to determine phenotype and a genotype correlations in Type 1 Diabetes
|
|
08-2016
|
The JDRF nPOD Viral Work Group: nPOD V
The JDRF nPOD Viral Work Group: nPOD V
|
|
06-2016
|
Identifying the contribution of beta cell dysfunction and autoimmunity to the pathogenesis of type 1 diabetes
Identifying the contribution of beta cell dysfunction and autoimmunity to the pathogenesis of type 1 diabetes
|
|
01-2016
|
Immune Tolerance Network
Immune Tolerance Network
|
|
12-2015
|
Helmsley Trust Diabetes Cell Repository
Helmsley Trust Diabetes Cell Repository
|
|
12-2015
|
Brehm Coalition-Dedifferentiation
Brehm Coalition-Dedifferentiation
|
|
08-2015
|
Protein markers to type 1 diabetes progression
Protein markers to type 1 diabetes progression
|
|
06-2015
|
Sanford Fellowship Project
Sanford Fellowship Project
|
|
04-2015
|
The Network for Open Source Data in Type 1 Diabetes
The Network for Open Source Data in Type 1 Diabetes
|
|
02-2015
|
Reversing Type 1 Diabetes After it is Established: A Pil
Reversing Type 1 Diabetes After it is Established: A Pil
|
|
12-2014
|
JDRF/ITN Partnership in Immune Tolerance: A Consortium
JDRF/ITN Partnership in Immune Tolerance: A Consortium
|
|
12-2014
|
Characterizing The Autoimmune Microbiome For Type 1 Diab
Characterizing The Autoimmune Microbiome For Type 1 Diab
|
|
12-2014
|
nPOD Coordinating Center
nPOD Coordinating Center
|
|
08-2014
|
Protein markers to type 1 diabetes progression
Protein markers to type 1 diabetes progression
|
|
04-2014
|
Preventing Type 1 Diabetes by oral delivery of plant-der
Preventing Type 1 Diabetes by oral delivery of plant-der
|
|
03-2014
|
2014 JDRF-Helmsley nPOD Annual Scientific Symposium
2014 JDRF-Helmsley nPOD Annual Scientific Symposium
|
|
02-2014
|
Ex Vivo Analysis of the Cell Educator System
Ex Vivo Analysis of the Cell Educator System
|
|
02-2014
|
The role of beta cell (dys)function ... (Rowe, P.)
The role of beta cell (dys)function ... (Rowe, P.)
|
|
01-2014
|
nPOD-V Meeting in Victoria
nPOD-V Meeting in Victoria
|
|
12-2013
|
The Diabetes Center Summit: Operations, Management and Q
The Diabetes Center Summit: Operations, Management and Q
|
|
12-2013
|
JDRF/ITN Partnership in Immune Tolerance: A Consortium
JDRF/ITN Partnership in Immune Tolerance: A Consortium
|
|
09-2013
|
Cord Blood Therapies for TYpe 1 DIabetes
Cord Blood Therapies for TYpe 1 DIabetes
|
|
08-2013
|
nPOD Expansion
nPOD Expansion
|
|
04-2013
|
Eval. optimal dose and therapeutic durability of CTB-
Eval. optimal dose and therapeutic durability of CTB-
|
|
04-2013
|
Immune Function and the Progression to Type 1 Diabetes
Immune Function and the Progression to Type 1 Diabetes
|
|
12-2012
|
JDRF/ITN Partnership in Immune Tolerance: A Consortium
JDRF/ITN Partnership in Immune Tolerance: A Consortium
|
|
12-2012
|
IL-2 Deficiency Associated Neuropathology
IL-2 Deficiency Associated Neuropathology
|
|
12-2012
|
Organ Processing and Pathology Core
Organ Processing and Pathology Core
|
|
09-2012
|
Anti-CD20 and oral insulin on reversal of T1D in NOD mic
Anti-CD20 and oral insulin on reversal of T1D in NOD mic
|
|
08-2012
|
A STUDY OF MODEL B-CELLS IN DIABETES TREATMENT
A STUDY OF MODEL B-CELLS IN DIABETES TREATMENT
|
|
07-2012
|
Smart Home-based Health Platform for Behavioral Monitori
Smart Home-based Health Platform for Behavioral Monitori
|
|
05-2012
|
Anti-CD20 and oral insulin on reversal of type 1 diabete
Anti-CD20 and oral insulin on reversal of type 1 diabete
|
|
05-2011
|
Structure Guided Small Molecule Targeting of Anti-Insuli
Structure Guided Small Molecule Targeting of Anti-Insuli
|
|
03-2011
|
Short Course G-CSF as Immunomodulatory Therapy for Type
Short Course G-CSF as Immunomodulatory Therapy for Type
|
|
02-2011
|
STAT5 Dysfunction as a Biomarker for Autoimmune Disease
STAT5 Dysfunction as a Biomarker for Autoimmune Disease
|
|
08-2010
|
ARRA Supplement P01AI042288
ARRA Supplement P01AI042288
|
|
08-2010
|
Ident of Autoantigens in T1D by Protein Microarray
Ident of Autoantigens in T1D by Protein Microarray
|
|
07-2010
|
Dendretic Cells and the Prevention of Type 1 Diabetes
Dendretic Cells and the Prevention of Type 1 Diabetes
|
|
06-2010
|
MISCELLANEOUS SPONSORS
MISCELLANEOUS SPONSORS
|
|
08-2009
|
Elan Pharmaceuticals PBMC Processing
Elan Pharmaceuticals PBMC Processing
|
|
07-2009
|
Cord Blood Immunoregulation of Type 1 Diabetes
Cord Blood Immunoregulation of Type 1 Diabetes
|
|
06-2009
|
Novel Mechanisms and Therapies Targeting Dysfunctional
Novel Mechanisms and Therapies Targeting Dysfunctional
|
|
06-2009
|
Regulatory T Cell Deffects in Human T1D
Regulatory T Cell Deffects in Human T1D
|
|
06-2009
|
Ident of Autoantigens in T1D by Protein Microarray
Ident of Autoantigens in T1D by Protein Microarray
|
|
05-2009
|
PPG - Immunoregulatory Based Therapies for TYpe 1 Diabet
PPG - Immunoregulatory Based Therapies for TYpe 1 Diabet
|
|
05-2008
|
Immunoregulatory Based Therapies for Type 1 Diabetes
Immunoregulatory Based Therapies for Type 1 Diabetes
|
|
06-2007
|
Defining the Role of CFTR in Cystic Fibrosis Related Dia
Defining the Role of CFTR in Cystic Fibrosis Related Dia
|
|
06-2007
|
Novel Mechanisms and Therapies Targeting Dysfunctional E
Novel Mechanisms and Therapies Targeting Dysfunctional E
|
|
05-2007
|
Immunoregulatory Based Therapies for Type 1 Diabetes
Immunoregulatory Based Therapies for Type 1 Diabetes
|
|
05-2007
|
CORE A: IMMUNE FUNCTION AND THE PROGRESSION TO TYPE I
CORE A: IMMUNE FUNCTION AND THE PROGRESSION TO TYPE I
|
|
01-2007
|
Enhancement of Islet Viability
Enhancement of Islet Viability
|
|
06-2006
|
The Origins of Cystic Fibrosis Related Diabetes
The Origins of Cystic Fibrosis Related Diabetes
|
|
06-2006
|
JDRF Gene Therapy Center
JDRF Gene Therapy Center
|
|
05-2006
|
MECHANISMS OF IMMUNOTHERAPY IN IDD PREVENTION TRIALS
MECHANISMS OF IMMUNOTHERAPY IN IDD PREVENTION TRIALS
|
|
05-2006
|
Immuno Based Therapies for the Prev and Reversal of T1
Immuno Based Therapies for the Prev and Reversal of T1
|
|
07-2005
|
CORE C:TRANSDUCTION OF HEPATOCYTES WITH RECOMBINANT AAV
CORE C:TRANSDUCTION OF HEPATOCYTES WITH RECOMBINANT AAV
|
|
12-2004
|
GENE THERAPY CENTER FOR THE PREVENTION OF DIABETES AND D
GENE THERAPY CENTER FOR THE PREVENTION OF DIABETES AND D
|
|
11-2004
|
MUTATION DETECTION IN MURINE STAT GENE FAMILY
MUTATION DETECTION IN MURINE STAT GENE FAMILY
|
|
10-2004
|
A Novel Gene Therapy for improving Islet Transplantation
A Novel Gene Therapy for improving Islet Transplantation
|
|
07-2004
|
DENDRITIC CELL AND THE PREVENTION OF TYPE 1 DIABETES
DENDRITIC CELL AND THE PREVENTION OF TYPE 1 DIABETES
|
|
06-2004
|
CYTOKINE GENE THERAPY FOR THE PREVENTION OF TYPE 1 DIABE
CYTOKINE GENE THERAPY FOR THE PREVENTION OF TYPE 1 DIABE
|
|
06-2003
|
THE ROLE OF HEME OXYGENASE-1 IN PANCREATIC B-CELL SURVIV
THE ROLE OF HEME OXYGENASE-1 IN PANCREATIC B-CELL SURVIV
|
|
05-2003
|
DQB*0602 RELATIVES--MECHANISMS FOR DIABETES PROTECTION
DQB*0602 RELATIVES--MECHANISMS FOR DIABETES PROTECTION
|
|
01-2003
|
JDF 4-2000-947
JDF 4-2000-947
|
|
04-2002
|
ADMINISTRATIVE SUPPLEMENTAL SUPPORT: MECHANISMS OF
ADMINISTRATIVE SUPPLEMENTAL SUPPORT: MECHANISMS OF
|
|
01-2002
|
CYTOKINE MEDIATED GENE THERAPY FOR THE PREVENTION AND
CYTOKINE MEDIATED GENE THERAPY FOR THE PREVENTION AND
|
|
09-2001
|
MECHANISMS OF IMMUNOTHERAPY INIDD PREVENTION TRIALS
MECHANISMS OF IMMUNOTHERAPY INIDD PREVENTION TRIALS
|
|
08-2001
|
ADMINISTRATIVE SUPPLEMENT: IMMUNE FUNCTION and LOW RISK
ADMINISTRATIVE SUPPLEMENT: IMMUNE FUNCTION and LOW RISK
|
|
08-2001
|
CORE A: IMMUNE FUNCTION IN LOW RISK GENOTYPES IN IDD
CORE A: IMMUNE FUNCTION IN LOW RISK GENOTYPES IN IDD
|
|
08-2001
|
PROJECT III: IMMUNE FUNCTION IN LOW RISK GENOTYPES IN ID
PROJECT III: IMMUNE FUNCTION IN LOW RISK GENOTYPES IN ID
|
|
05-2000
|
DQB1*0602 RELATIVES: MECHANISMS CONFERRING DIABETES
DQB1*0602 RELATIVES: MECHANISMS CONFERRING DIABETES
|
|
03-2000
|
PHASE I/II TRIAL OF HOKT3 GAMMA 1 (A1A-A1A) FOR TREATMEN
PHASE I/II TRIAL OF HOKT3 GAMMA 1 (A1A-A1A) FOR TREATMEN
|
|
03-2000
|
THE ROLE FOR B-LYMPHOCYTES IN THE DEVELOPMENT OF ANTI-GA
THE ROLE FOR B-LYMPHOCYTES IN THE DEVELOPMENT OF ANTI-GA
|
|
01-1999
|
AUTOIMMUNITY TO GLUTAMATE DE- CARBOXYLASE IN IDD
AUTOIMMUNITY TO GLUTAMATE DE- CARBOXYLASE IN IDD
|
|
12-1998
|
INSULIN SECRETION and LYMPHOCYTE RECEPTOR EXPRESSION: KEY
INSULIN SECRETION and LYMPHOCYTE RECEPTOR EXPRESSION: KEY
|
|
09-1998
|
CELLUAR IMMUNITY TO GLOUTAMATE DECARBOXYLASE IN IDD
CELLUAR IMMUNITY TO GLOUTAMATE DECARBOXYLASE IN IDD
|
